152 related articles for article (PubMed ID: 29140706)
1. Galactosylated Pro-Drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis.
Di Guida F; Pirozzi C; Magliocca S; Santoro A; Lama A; Russo R; Nieddu M; Burrai L; Boatto G; Mollica MP; Sodano F; Lazzarato L; Chegaev K; Meli R; Raso GM; Rimoli MG
Mol Pharm; 2018 Jan; 15(1):21-30. PubMed ID: 29140706
[TBL] [Abstract][Full Text] [Related]
2. Enhanced biliary excretion of canalicular membrane enzymes in ethynylestradiol-induced cholestasis. Effects of ursodeoxycholic acid administration.
Arrese M; Pizarro M; Solís N; Koenig C; Accatino L
Biochem Pharmacol; 1995 Oct; 50(8):1223-32. PubMed ID: 7488238
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholate Restores Biliary Excretion of Methotrexate in Rats with Ethinyl Estradiol Induced-Cholestasis by Restoring Canalicular Mrp2 Expression.
Kim MJ; Kang YJ; Kwon M; Choi YA; Choi MK; Chi HY; Yoo HH; Shim CK; Song IS
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29642532
[TBL] [Abstract][Full Text] [Related]
4. UDCA and CDCA alleviate 17α-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats.
Li X; Yuan Z; Liu R; Hassan HM; Yang H; Sun R; Zhang L; Jiang Z
Toxicol Appl Pharmacol; 2016 Nov; 311():12-25. PubMed ID: 27743861
[TBL] [Abstract][Full Text] [Related]
5. Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis.
Razori MV; Maidagan PM; Ciriaci N; Andermatten RB; Barosso IR; Martín PL; Basiglio CL; Sánchez Pozzi EJ; Ruiz ML; Roma MG
Biochem Pharmacol; 2019 Oct; 168():48-56. PubMed ID: 31202734
[TBL] [Abstract][Full Text] [Related]
6. Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies.
Wang R; Liu L; Sheps JA; Forrest D; Hofmann AF; Hagey LR; Ling V
Am J Physiol Gastrointest Liver Physiol; 2013 Aug; 305(4):G286-94. PubMed ID: 23764895
[TBL] [Abstract][Full Text] [Related]
7. 3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats.
Clerici C; Castellani D; Asciutti S; Pellicciari R; Setchell KD; O'Connell NC; Sadeghpour B; Camaioni E; Fiorucci S; Renga B; Nardi E; Sabatino G; Clementi M; Giuliano V; Baldoni M; Orlandi S; Mazzocchi A; Morelli A; Morelli O
Toxicol Appl Pharmacol; 2006 Jul; 214(2):199-208. PubMed ID: 16487557
[TBL] [Abstract][Full Text] [Related]
8. Lack of benefit of ursodeoxycholic acid in drug-induced cholestasis in the rat.
Hillstrom J; Duane WC; Eckfeldt JH; Furne J; Levitt MD
Proc Soc Exp Biol Med; 1992 May; 200(1):122-6. PubMed ID: 1570353
[TBL] [Abstract][Full Text] [Related]
9. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
10. Hepatoprotection in ethinylestradiol-treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid.
Azer SA; Canfield PJ; Stacey NH
J Gastroenterol Hepatol; 1995; 10(3):261-9. PubMed ID: 7548801
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats.
Purucker E; Marschall HU; Winograd R; Matern S
Biochim Biophys Acta; 2001 Apr; 1526(1):44-52. PubMed ID: 11287121
[TBL] [Abstract][Full Text] [Related]
12. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
[TBL] [Abstract][Full Text] [Related]
13. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity.
Buryova H; Chalupsky K; Zbodakova O; Kanchev I; Jirouskova M; Gregor M; Sedlacek R
BMC Gastroenterol; 2013 Oct; 13():155. PubMed ID: 24172289
[TBL] [Abstract][Full Text] [Related]
14. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
Beuers U
Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
[TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G; Beuers U
Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
[TBL] [Abstract][Full Text] [Related]
16. Regulation of rat organic anion transporters in bile salt-induced cholestatic hepatitis: effect of ursodeoxycholate.
Rost D; Herrmann T; Sauer P; Schmidts HL; Stieger B; Meier PJ; Stremmel W; Stiehl A
Hepatology; 2003 Jul; 38(1):187-95. PubMed ID: 12830001
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of SRT1720 via the HNF1α/FXR signalling pathway and anti-inflammatory mechanisms in mice with estrogen-induced cholestatic liver injury.
Yu L; Liu X; Li X; Yuan Z; Yang H; Zhang L; Jiang Z
Toxicol Lett; 2016 Dec; 264():1-11. PubMed ID: 27818225
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
[TBL] [Abstract][Full Text] [Related]
19. Fibrates and cholestasis.
Ghonem NS; Assis DN; Boyer JL
Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
